Showing 1‐3 of 3
results per page
23 Jun 2021
CellPoint and Lonza to Leverage the Cocoon Platform for T-Cell Therapeutics Manufactured at the Point-of-Care
CellPoint and Lonza will collaborate to rapidly develop several T-cell based therapies and utilize the Cocoon® Platform for clinical point-of-care manufacturing The goal is to...
23 Apr 2021
Lonza Announces Construction of a New Small Molecule Manufacturing Complex in Visp
Lonza will invest CHF 200 million to construct a new manufacturing complexThe 2000 m2 complex will include a customer dedicated manufacturing line...
16 Feb 2021
Lonza Expands Solid Form Services for Small Molecule Drugs
Solid Form Services encompass all aspects of solid form screening and characterization of small molecule APIsOffering designed to complement Lonza API development services and...